Every so often, an idea appears that forces me to pause, re-examine the science, and ask whether we have misunderstood something important. This happened recently while I was working through the final stages of our long-COVID framework and reviewing the core pathophysiology that seems to drive so many of the strange, multi-system symptoms patients experience.
As I reflected on the patterns, I returned once again to a principle that has guided me for years:
“All diseases are simple—if you understand them.”
And in long COVID, one anatomical structure keeps emerging as central to the entire symptom cluster: the vagus nerve, specifically the nodose ganglion, located just behind the throat. Increasingly, this region appears inflamed in many long-COVID sufferers, and that inflammation may be driving an extraordinary range of symptoms—autonomic dysfunction, gut issues, shortness of breath, nausea, heart-rate instability, and even cognitive changes.
The Unexpected Discovery: GLP-1 Receptors Are Abundant Here
While exploring this, I had what I first thought was a “throwaway” idea:
Could GLP-1 receptors—best known for their role in weight loss drugs—also be present in the nodose ganglion?
So I checked.
To my surprise, the nodose ganglion turns out to be one of the highest-density locations for GLP-1 receptors in the body.
This changes the conversation completely.
GLP-1 signaling plays a major role in:
inflammation suppression
autonomic stability
vagal–brain communication
metabolic homeostasis
neuronal healing
If long COVID (in some individuals) is in part a vagal inflammatory disorder, then a class of drugs that directly modulates inflammation and excitability in the nodose ganglion becomes far more relevant than previously realized.
This is the first time we’ve had a plausible pharmacological pathway that directly targets the anatomical structure I believe is inflamed in long COVID.
Could GLP-1 Agonists Actually Help Long-COVID Patients?
Let me be clear: I am not suggesting that everyone with long COVID should go out and obtain GLP-1 agonists.
What I am suggesting is that there is a strong theoretical basis for why these medications might help a subset of patients—specifically those whose symptoms map strongly onto vagal inflammation:
dizziness
breathlessness or air hunger
heart-rate instability
nausea
loss of appetite
gut dysmotility
temperature intolerance
sudden “vagal surges”
abnormal fatigue patterns
These are exactly the symptoms consistent with nodose ganglion inflammation, and this is the group most likely to benefit.
In fact, several trials have already begun—tirzepatide being one of the drugs under early investigation. The challenge, which I’ve become increasingly concerned about, is patient selection.
The Coming Problem: If We Don’t Select the Right Patients, The Trials Will Fail
Most long-COVID studies so far have made a critical mistake:
they treat long COVID as one single disorder. It isn’t.
If you include every possible phenotype—post-viral ME/CFS-like patients, microvascular injury, autoimmune sequelae, post-critical-care syndromes, mast-cell patterns—then an intervention targeted at vagal inflammation will dilute into statistical noise.
If researchers fail to identify the vagal-inflammation subgroup, GLP-1 trials will appear negative—even if the drug works for the right people.
This is how the scientific community repeatedly misses therapeutic signals.
We must stratify.
Identify patients with vagal involvement
Track their symptom clusters
Measure their response
Separate them from other long-COVID phenotypes
Without this, every study runs the risk of being written off before the true signal is even discovered.
What I Want Researchers to Understand
There is a primary driver in each person—an underlying inflammatory mechanism that links their timeline to their symptoms. If we don’t identify that driver first, every treatment becomes guesswork.
And in long COVID, the nodose ganglion appears to be a central hub through which many core symptoms are generated or amplified. If this region remains inflamed, the body struggles to reset its autonomic balance, its gut signaling, its respiratory reflexes, and even its cardiovascular stability.
If GLP-1 agonists can modulate this inflammation, then—at least theoretically—they may help rebuild that system more effectively than anything we’ve tried so far.
Where I Stand Now
After years of research, thousands of patient observations, and a relentless effort to understand the fog of symptoms, I finally feel I am seeing the shape of the problem clearly.
Long COVID is not mysterious—it’s misunderstood.
And unless we design studies differently, we will miss the first real opportunity for meaningful recovery.
I expect to publish our full paper on this soon, and I believe it will provide a much-needed framework for making sense of long COVID’s diverse symptoms. But the insights around GLP-1 receptors and the nodose ganglion may be one of the most intriguing—and clinically actionable—pieces of the puzzle so far.
Thank you for taking the time to read, reflect, and stay engaged.
